Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study

Rory Sheehan, Laura Horsfall, André Strydom, David Osborn, Kate Walters, Angela Hassiotis, Rory Sheehan, Laura Horsfall, André Strydom, David Osborn, Kate Walters, Angela Hassiotis

Abstract

Objectives: To measure the incidence of movement side effects of antipsychotic drugs in adults with intellectual disability and compare rates with adults without intellectual disability.

Design: Cohort study using data from The Health Improvement Network.

Setting: UK primary care.

Participants: Adults with intellectual disability prescribed antipsychotic drugs matched to a control group of adults without intellectual disability prescribed antipsychotic drugs.

Outcome measures: New records of movement side effect including acute dystonias, akathisia, parkinsonism, tardive dyskinaesia and neuroleptic malignant syndrome.

Results: 9013 adults with intellectual disability and a control cohort of 34 242 adults without intellectual disability together contributed 148 709 person-years data. The overall incidence of recorded movement side effects was 275 per 10 000 person-years (95% CI 256 to 296) in the intellectual disability group and 248 per 10 000 person-years (95% CI 237 to 260) in the control group. The incidence of any recorded movement side effect was significantly greater in people with intellectual disability compared with those without (incidence rate ratio 1.30, 95% CI 1.18 to 1.42, p<0.001, after adjustment for potential confounders), with parkinsonism and akathisia showing the greatest difference between the groups. Neuroleptic malignant syndrome, although occurring infrequently, was three times more common in people with intellectual disability-prescribed antipsychotic drugs (incidence rate ratio 3.03, 95% CI 1.26 to 7.30, p=0.013). Differences in rates of movement side effects between the groups were not due to differences in the proportions prescribed first and second-generation antipsychotic drugs.

Conclusions: This study provides evidence to substantiate the long-held assumption that people with intellectual disability are more susceptible to movement side effects of antipsychotic drugs. Assessment for movement side effects should be integral to antipsychotic drug monitoring in people with intellectual disability. Regular medication review is essential to ensure optimal prescribing in this group.

Keywords: Adverse Events; Mental Health; Psychiatry.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Time trends in crude incidence rates of (A) movement side effect defined by Read code and (B) antimuscarinic drug prescription in people with and without ID prescribed antipsychotic drugs. ID, intellectual disability.

References

    1. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980;10:55–72. 10.1017/S003329170003960X
    1. Leucht S, Wahlbeck K, Hamann J, et al. . New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581–9. 10.1016/S0140-6736(03)13306-5
    1. Cooper SA, Smiley E, Morrison J, et al. . Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry 2007;190:27–35. 10.1192/bjp.bp.106.022483
    1. Sheehan R, Hassiotis A, Walters K, et al. . Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ 2015;351:h4326 10.1136/bmj.h4326
    1. Deb S, Sohanpal SK, Soni R, et al. . The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. J Intellect Disabil Res 2007;51:766–77. 10.1111/j.1365-2788.2007.00950.x
    1. Arnold LE. Clinical pharmacological issues in treating psychiatric disorders of patients with mental retardation. Ann Clin Psychiatry 1993;5:189–97. 10.3109/10401239309148982
    1. Cunningham-Owens DG. Special populations A guide to extrapyramidal side-effects of antipsychotic drugs. 2nd ed Cambridge, UK: Cambridge University Press, 2014.
    1. Blak BT, Thompson M, Dattani H, et al. . Generalisability of the Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251–5. 10.14236/jhi.v19i4.820
    1. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171–7. 10.14236/jhi.v12i3.124
    1. Booth N. What are the Read Codes? Health Libr Rev 1994;11:177–82.
    1. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009;18:76–83. 10.1002/pds.1688
    1. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf 2013;22:64–9. 10.1002/pds.3368
    1. Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf 2009;18:704–7. 10.1002/pds.1770
    1. Lewis JD, Bilker WB, Weinstein RB, et al. . The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005;14:443–51. 10.1002/pds.1115
    1. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the North. Routledge 1988.
    1. Marston L, Nazareth I, Petersen I, et al. . Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2014;4:e006135 10.1136/bmjopen-2014-006135
    1. Frighi V, Stephenson MT, Morovat A, et al. . Safety of antipsychotics in people with intellectual disability. Br J Psychiatry 2011;199:289–95. 10.1192/bjp.bp.110.085670
    1. Gagiano C, Read S, Thorpe L, et al. . Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology 2005;179:629–36. 10.1007/s00213-004-2093-2
    1. Leucht S, Cipriani A, Spineli L, et al. . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951–62. 10.1016/S0140-6736(13)60733-3
    1. Peluso MJ, Lewis SW, Barnes TR, et al. . Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 2012;200:387–92. 10.1192/bjp.bp.111.101485
    1. Scheifes A, Walraven S, Stolker JJ, et al. . Movement disorders in adults with intellectual disability and behavioral problems associated with use of antipsychotics. J Clin Psychopharmacol 2016;36:308–13. 10.1097/JCP.0000000000000528
    1. de Kuijper G, Mulder H, Evenhuis H, et al. . Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. Research Dev Disabil 2013;34:2799–809. 10.1016/j.ridd.2013.05.016
    1. Matson JL, Fodstad JC, Neal D, et al. . Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use. Res Dev Disabil 2010;31:108–16. 10.1016/j.ridd.2009.08.002
    1. Rogers D, Karki C, Bartlett C, et al. . The motor disorders of mental handicap. An overlap with the motor disorders of severe psychiatric illness. Br J Psychiatry 1991;158:97–102. 10.1192/bjp.158.1.97
    1. Guy W. Abnormal involuntary movement scale ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare, 1976.
    1. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672–6. 10.1192/bjp.154.5.672
    1. Simpson GM, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45:11–19. 10.1111/j.1600-0447.1970.tb02066.x
    1. Viejo LF, Morales V, Puñal P, et al. . Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 2003;107:45–9. 10.1034/j.1600-0447.2003.02385.x
    1. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986;73:337–47. 10.1111/j.1600-0447.1986.tb02694.x
    1. Boyd RD. Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases. Am J Ment Retard 1993;98:143–55.
    1. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4–10. 10.1111/j.1600-0447.2009.01425.x
    1. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008;23:S15–S26. 10.1002/hup.918
    1. Crossley R, Withers P. Antipsychotic medication and people with Intellectual Disabilities: their knowledge and experiences. J Applied Research in Intellectual Disabilities 2009;22:77–86. 10.1111/j.1468-3148.2008.00454.x
    1. Lennox NG, Diggens JN, Ugoni AM. The general practice care of people with intellectual disability: barriers and solutions. J Intellect Disabil Res 1997;41:380–90. 10.1111/j.1365-2788.1997.tb00725.x
    1. Schouten HJ, Knol W, Egberts TC, et al. . Quality of life of elderly patients with antipsychotic-induced parkinsonism: a cross-sectional study. J Am Med Dir Assoc 2012;13:82.e1–82.e5. 10.1016/j.jamda.2010.12.003
    1. Scheifes A, Walraven S, Stolker JJ, et al. . Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. Res Dev Disabil 2016;49-50:13–21. 10.1016/j.ridd.2015.11.017
    1. Paton C, Bhatti S, Purandare K, et al. . Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice. BMJ Open 2016;6:e013116 10.1136/bmjopen-2016-013116
    1. Sheehan R, Hassiotis A. Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. Lancet Psychiatry 2017;4:238–56. 10.1016/S2215-0366(16)30191-2

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren